Drug Profile

Hepatocyte growth factor therapy - Kringle Pharma/ChronTech Pharma

Alternative Names: ChronSeal

Latest Information Update: 16 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kringle Pharma; Tripep
Developer ChronTech Pharma; Kringle Pharma
Class Antifibrotics; Growth factors; Neuropsychotherapeutics
Mechanism of Action Hepatocyte growth factor stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Leg ulcer

Most Recent Events

18 Jun 2014 No development reported - Phase-I/II for Leg ulcer in Norway (Topical)
18 Jun 2014 No development reported - Phase-I/II for Leg ulcer in Sweden (Topical)
21 Apr 2011 Clinical development is ongoing

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com